Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 30, 2013

View Archived Issues

Trametinib dimethyl sulfoxide plus gemcitabine does not improve outcomes in pancreatic cancer

Results presented from phase II trial of axitinib in hepatocellular carcinoma

Bristol-Myers Squibb reviews progress of fourth quarter 2012

Algeta begins research program on epratuzumab-based targeted thorium conjugate

Phase III APEX study to be expanded into China

AiCuris passes enrollment milestone in phase II pritelivir study

CNRS discloses novel antibodies for cancer and other disorders

Kalvista Pharmaceuticals synthesizes new plasma kallikrein inhibitors

New PDE2A/PDE10A inhibitors disclosed by Janssen Pharmaceutical

Japanese group divulges new mraY inhibitors for bacterial infections

New antibacterial cephem compounds reported by Shionogi & Co.

Shionogi & Co. presents novel agents for HIV

Combination of luminespib and capecitabine well tolerated

Results from the first of two phase III tavaborole trials reported

Acceleron begins phase II study of ACE-536 for anemia in MDS

4-Antibody and the Ludwig Institute expand oncology antibody program

Prosensa's Duchenne muscular dystrophy products achieve orphan drug status

IRL-1620 demonstrates neuroprotection in cerebral ischemia model

OncoPep begins phase I/IIa trial of multipeptide vaccine in smoldering multiple myeloma

FDA clears IND application for ICT-140

FDA approves Kynamro for homozygous familial hypercholesterolemia

FDA advisory committee recommends approval of olodaterol for COPD

Kissei seeks Japanese approval of dexrazoxane for use in anthracycline extravasation

OrbeShield granted fast track designation for gastrointestinal ARS

ElMindA and Purdue Pharma establish research agreement in pain

Genentech licenses rights to Afraxis compounds

Biotecnol and Chiome to codevelop antibodies for cancer